RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions

Trial Profile

RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Bivalirudin (Primary)
  • Indications Thrombosis
  • Focus Therapeutic Use
  • Acronyms RIAPRE
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 10 May 2012 New trial record
    • 04 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top